Rational Targeted Therapeutics for Double-Hit Lymphoma

Azizian, Nancy G.; Liu, Yuanhui; Pham, Lan V.; Li, Yulin

doi:10.2217/ijh-2019-0009

Cited by 2 publications

(1 citation statement)

References 21 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further epidemiologic analysis of DHL/THL and DEL cases reveals an incidence of 2%-12% and 19%-34% among the DLBCL, respectively [9] . Given their dismal outcome, in the last few years since the WHO revised the classification, several reviews in the literature have pinpointed these diseases as an unmet medical need [8,[10][11][12][13] .…”

Section: High-grade B-cell Lymphomasmentioning

confidence: 99%

Targeting MYC-driven lymphoma: lessons learned and future directions

Martínez-Martín¹,

Beaulieu²,

Soucek³

2023

Cancer Drug Resist

View full text Add to dashboard Cite

MYC plays a central role in tumorigenesis by orchestrating cell proliferation, growth and survival, among other transformation mechanisms. In particular, MYC has often been associated with lymphomagenesis. In fact, MYC overexpressing lymphomas such as high-grade B-cell lymphoma (HGBL) and double expressor diffuse large B-cell lymphomas (DLBCL), are considered addicted to MYC. In such a context, MYC targeting therapies are of special interest, as MYC withdrawal is expected to result in tumor regression. However, whether high MYC levels are always predictive of increased sensitivity to these approaches is not clear yet. Even though no MYC inhibitor has received regulatory approval to date, substantial efforts have been made to investigate avenues to render MYC a druggable target. Here, we summarize the different classes of molecules currently under development, which mostly target MYC indirectly in aggressive B-cell lymphomas, paying special attention to subtypes with MYC/BCL2 or BCL6 translocations or overexpression.

show abstract